NCT03915860View on ClinicalTrials.gov

Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

PHASE3CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

March 27, 2019

Primary Completion Date

December 23, 2019

Study Completion Date

December 23, 2019

Conditions
Acne Vulgaris
Interventions
DRUG

Trifarotene

Topical Cream

Trial Locations (9)

19103

Galderma Investigational Site, Philadelphia

72916

Galderma Investigational Site, Fort Smith

75062

Galderma Investigational Site, Irving

75081

Galderma Investigational Site, Richardson

77701

Galderma Investigational Site, Beaumont

78660

Galderma Investigational Site, Pflugerville

78759

Galderma Investigational Site, Austin

01915

Galderma Investigational Site, Beverly

03801

Galderma Investigational Site, Portsmouth

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY

NCT03915860 - Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris | Biotech Hunter | Biotech Hunter